- Friedenstein A.J., Chailakhjan R.K. & Lalykina K.S. (1970): The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells. Cell and Tissue Kinetics. 3:393–403.
- Chawla L.S., Bellomo R., Bihorac A., et al. (2017): Acute kidney disease and renal recovery: Consensus report of the Acute Disease Quality Initiative (ADQI) 16 Workgroup. Nat. Rev. Nephrol. 13:241– 257.
- Sávio-Silva C., Beyerstedt S., Soinski-Sousa P.E., et al. (2020): Mesenchymal Stem Cell Therapy for Diabetic Kidney Disease: A Review of the Studies Using Syngeneic, Autologous, Allogeneic, and Xenogeneic Cells. Stem Cells Int. 2020:1–28.
- Cheng G.S., Wang X.Y., Li Y.X., et al. (2017): Let-7a-transfected mesenchymal stem cells ameliorate monocrotaline-induced pulmonary hypertension by suppressing pulmonary artery smooth muscle cell growth through STAT3-BMPR2 signaling. Stem Cell Res. Ther. 8: 11.
- Christov M., Waikar S.S., Pereira R.C., et al. (2013): Plasma FGF23 levels increase rapidly after acute kidney injury. Kidney Int. 84: 639– 641.
- Da Cruz Junho C.V., Caio‐Silva W., Ruiz‐Hurtado G., et al. (2019): Characterization of Klotho/FGF23 signaling in cardiorenal syndrome‐ induced cardiac hypertrophy. The FASEB Journal. 33: 831.1-831.1.
- Raafat N., Abdel Aal S., Abdo F., et al. (2015): Mesenchymal stem cells, In vivo therapeutic application ameliorates carbon tetrachloride induced liver fibrosis in rats. The International Journal of Biochemistry and Cell Biology. 68: 109–118.
- Richter M., Lautze H.J., Walther T., et al. (2015): The failing heart is a major source of circulating FGF23 via oncostatin M receptor activation. J Heart Lung Transplant. 34:1211–1214.
- Christov M., Waikar S.S., Pereira R.C., et al. (2013): Plasma FGF23 levels increase rapidly after acute kidney injury. Kidney Int. 84: 639– 641.
- Leifheit-Nestler M., Grabner A., Hermann L., et al. (2017): Vitamin D treatment attenuates cardiac FGF23/FGFR4 signaling and hypertrophy in uremic rats. Nephrol Dial Transplant. 32:1493–1503.
- Mace M.L., Gravesen E., Nordholm A., et al. (2017): Kidney fibroblast growth factor 23 does not contribute to elevation of its circulating levels in uremia. Kidney Int. 92:165-178.
- Leaf D.E., Siew E.D., Eisenga M.F., et al. (2018): Fibroblast growth factor 23 associates with death in critically ill patients. Clin J Am Soc Nephrol. 13:531-541.
- Shi M., McMillan K.L., Wu J., et al. (2018): Cisplatin nephrotoxicity as a model of chronic kidney disease. Lab Invest. 98:1105–1121.
- Hu M.C., Shi M., Zhang J., et al. (2010): Klotho deficiency is an early biomarker of renal ischemia–reperfusion injury and its replacement is protective. Kidney Int. 78: 1240–1251.
- Hu M.C., Kuro-O M. & Moe O.W. (2013): Klotho and Chronic Kidney Disease. Contrib. Nephrol. 180:47–63.
- Kim A.J., Ro H., Kim H., et al. (2016): Klotho and S100A8/A9 as discriminative markers between pre-renal and intrinsic acute kidney injury. PLoS One. 11:e0147255.
- Seo M.Y., Yang J., Lee J.Y., et al. (2015): Renal klotho expression in patients with acute kidney injury is associated with the severity of the injury. Korean J Intern Med. 30:489-495.
- Bian A., Neyra J.A., Zhan M., et al. (2015): Klotho, stem cells, and aging. Clin Interv Aging. 10:1233-43.
- Ni W., Fang Y., Xie L., et al. (2015): Adipose-Derived Mesenchymal Stem Cells Transplantation Alleviates Renal Injury in Streptozotocin- Induced Diabetic Nephropathy. J. Histochem. Cytochem. 63:842–853.
- Kieswich J.E., Chen J., Alliouachene S., et al. (2018): A novel model of reno-cardiac syndrome in the C57BL/ 6 mouse strain. BMC Nephrol. 19:346.
- Zhu F., Chong L.O., Pei G., et al. (2017): Adipose-derived mesenchymal stem cells employed exosomes to attenuate AKI-CKD transition through tubular epithelial cell dependent Sox9 activation. Oncotarget. 8:70707–70726.
- Rodrigues C.E., Capcha J.M., de Braganca A.C., et al. (2017): Human umbilical cord-derived mesenchymal stromal cells protect against premature renal senescence resulting from oxidative stress in rats with acute kidney injury. Stem Cell Res. Ther. 8:19.
- Florea V., Rieger A.C., DiFede D.L., et al. (2017): Dose Comparison Study of Allogeneic Mesenchymal Stem Cells in Patients with Ischemic Cardiomyopathy (The TRIDENT Study). Circ. Res. 121:1279–1290.
- Alatab S., Shekarchian S., Najafi I., et al. (2019): Systemic Infusion of Autologous Adipose Tissue-Derived Mesenchymal Stem Cells in Peritoneal Dialysis Patients: Feasibility and Safety. Cell J. 20:483–495.
- Saad A., Dietz A.B., Herrmann S.M.S., et al. (2017): Autologous Mesenchymal Stem Cells Increase Cortical Perfusion in Renovascular Disease. J. Am. Soc. Nephrol. 28:2777–2785.
- Swaminathan M., Stafford-Smith M., Chertow G.M., et al. (2018): Allogeneic Mesenchymal Stem Cells for Treatment of AKI after Cardiac Surgery. J. Am. Soc. Nephrol. 29:260–267.
- Makhlough A., Shekarchian S., Moghadasali R., et al. (2017): Safety and tolerability of autologous bone marrow mesenchymal stromal cells in ADPKD patients. Stem Cell Res. Ther. 8:116.
- Lin W., Li H.Y., Yang Q., et al. (2021): Administration of mesenchymal stem cells in diabetic kidney disease: A systematic review and meta-analysis. Stem Cell Res. Ther. 12:1–21.
|